@article{fdi:010057314,
  title = {{A} real-life study of the use, effectiveness and tolerability of rosiglitazone in {F}rance : {T}he {AVANCE} study},
  author = {{H}alimi, {S}. and {A}ubert, {J}. {P}. and {F}ontbonne, {A}nnick and {G}uillausseau, {P}. {J}. and {N}achit, {F}. and {B}ouee, {S}. and {D}etournay, {B}.},
  editor = {},
  language = {{ENG}},
  abstract = {{A}im. - {T}he study aimed to determine the effectiveness and tolerability of rosiglitazone, and its profile in terms of treatment adherence, treated patients and prescribing recommendations under everyday conditions of care. {M}ethods. - {T}his was a "real-life" observational longitudinal study including patients with type 2 diabetes mellitus ({T}2{DM}) starting treatment with rosiglitazone and followed for up to 2 years. {A} questionnaire was completed at the time of inclusion and during routine consultations at around 6, 12, 18 and 24 months following inclusion. {I}nformation was collected on sociodemographics, clinical history, treatments, co-morbidities, laboratory data and compliance with treatment. {T}here were three primary outcome measures: treatment response (defined as an {H}b{A}(1c) <= 8.0% or a decrease in {H}b{A}(1c) >= 0.7%); switch to insulin (as considered necessary by the physician); and occurrence of adverse events requiring a change or discontinuation of treatment. {R}esults. - {T}he evaluation included 670 patients (61.1%) treated with rosiglitazone/metformin as fixed-dose combination tablets and 427 (38.9%) with standard rosiglitazone tablets. {R}ates of {H}b{A}(1c) response, defined as an {H}b{A}(1c) less than or equal to 8.0% or a decrease in {H}b{A}(1c) greater than or equal to 0.7%, ranged from 80.6% to 92.1% depending on the follow-up time. {T}he percentage of patients with an {H}b{A}(1c) less than 7% was 18.4% before rosiglitazone was prescribed, and ranged from 48.2% to 57.8% depending on the follow-up period. {S}ixty-two patients (6.1%, 95% {CI}: 4.6-7.6%) switched to insulin therapy during the follow-up period. {S}pontaneously reported adverse events leading to a change or discontinuation of treatment were seen in 45 patients (4.4%, 95% {CI}: 3.2-5.6%). {C}onclusion. - {R}osiglitazone showed sustained efficacy, with around 90% of patients defined as responders to the treatment in terms of reduction in {H}b{A}(1c), and was relatively well tolerated. {T}he adverse-event profile was consistent with the known effects of rosiglitazone, and no signs of increased cardiovascular ischaemic risk were observed. {T}hese results are in agreement with previous studies on rosiglitazone.},
  keywords = {{T}ype 2 diabetes ; {R}osiglitazone ; {E}fficacy ; {T}olerability ; {O}bservational study},
  booktitle = {},
  journal = {{D}iabetes and {M}etabolism},
  volume = {38},
  numero = {4},
  pages = {343--351},
  ISSN = {1262-3636},
  year = {2012},
  DOI = {10.1016/j.diabet.2012.03.002},
  URL = {https://www.documentation.ird.fr/hor/fdi:010057314},
}